New gut cleaner could make colon surgery safer

NCT ID NCT07180615

Not yet recruiting Disease control Sponsor: Universität Luzern Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a gut-cleaning routine using rifaximin works as well as the standard neomycin/metronidazole combination to prevent infections after colon surgery. About 458 adults having planned colon surgery will take one of the two treatments the day before surgery. Researchers will track infections, deaths, and hospital stay length for 30 days after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rifaximin (Xifaxan) or Neomycin/Metronidazole
What this could lead to: If it works, this could offer a simpler, better-tolerated gut-cleaning option before colon surgery to reduce infection risk.
What could go wrong: This is a phase 4 trial comparing two established drugs, so major surprises are unlikely. The main risk is that rifaximin may not prevent infections as effectively as the standard combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Surgical Wound Infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON SURGERY SURGICAL SITE INFECTION SURGICAL SITE INFECTIONS

Contacts and locations

Locations

Kantonsspital Aarau

Aarau, 5001, Switzerland
Kantonsspital St. Gallen

Sankt Gallen, 9007, Switzerland
Luzerner Kantonsspital

Lucerne, 6006, Switzerland
Stadtspital Triemli

Zurich, 8063, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.